articleAnnals of Internal MedicineMar 2, 2004Closed access

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

SJStephanos J. HadziyannisHSHoel SetteTRTimothy R. MorganVBVijayan BalanMDMoises Diago

University of Göttingen · Scripps Clinic · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C.

Objective

To assess the efficacy and safety of 24 or 48 weeks of treatment with peginterferon-alpha2a plus a low or standard dose of ribavirin.

Citation impact

2,837
total citations
FWCI
116.92
Percentile
100%
References
20
Citations per year

Authors

15

Topics & keywords

Keywords
  • Ribavirin
  • Medicine
  • Internal medicine
  • Gastroenterology
  • Hepatitis C
  • Alpha interferon
  • Hepatitis C virus
  • Interferon
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.